Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Leber’s Hereditary Optic Neuropathy (LHON) Therapeutic Pipeline Market Review, H2 2016

Thursday, October 20, 2016 1:05
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Summary

‘Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) – Pipeline Review, H2 2016’, provides an overview of the Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) and features dormant and discontinued projects.

Request a sample report @ https://www.wiseguyreports.com/sample-request/693291-leber-s-hereditary-optic-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) 
- The report reviews pipeline therapeutics for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) therapeutics and enlists all their major and minor projects 
- The report assesses Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) pipeline depth and focus of Indication therapeutics 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ https://www.wiseguyreports.com/enquiry/693291-leber-s-hereditary-optic-review-h2-2016   

Key points in table of content

Table of Contents 2 
List of Tables 4 
List of Figures 5 
Introduction 6 
Report Coverage 6 
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) Overview 7 
Therapeutics Development 8 
Pipeline Products for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) – Overview 8 
Pipeline Products for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) – Comparative Analysis 9 
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) – Therapeutics under Development by Companies 10 
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) – Therapeutics under Investigation by Universities/Institutes 11 
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) – Pipeline Products Glance 12 
Late Stage Products 12 
Clinical Stage Products 13 
Early Stage Products 14 
Unknown Stage Products 15 
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) – Products under Development by Companies 16 
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) – Products under Investigation by Universities/Institutes 17 
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) – Companies Involved in Therapeutics Development 18 
Alkeus Pharmaceuticals, Inc. 18 
Biovista Inc. 19 
GenSight Biologics S.A. 20 
Ixchel Pharma, LLC 21 
Khondrion BV 22 
Spark Therapeutics, Inc. 23 
Stealth BioTherapeutics Inc. 24 
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) – Therapeutics Assessment 25 
Assessment by Monotherapy Products 25 
Assessment by Target 26 
Assessment by Mechanism of Action 28 
Assessment by Route of Administration 30 
Assessment by Molecule Type 32 
Drug Profiles 34 
BVA-202 – Drug Profile 34 
Product Description 34 
Mechanism Of Action 34 
R&D Progress 34 
BVA-203 – Drug Profile 35 
Product Description 35 
Mechanism Of Action 35 
R&D Progress 35 
Drug for Lebers Hereditary Optic Neuropathy – Drug Profile 36 
Product Description 36 
Mechanism Of Action 36 
R&D Progress 36 
elamipretide – Drug Profile 37 
Product Description 37 
Mechanism Of Action 37 
R&D Progress 37 
Gene Therapy to Activate ND4 for Leber’s Hereditary Optic Neuropathy – Drug Profile 43 
Product Description 43 
Mechanism Of Action 43 
R&D Progress 43 
GS-010 – Drug Profile 44 
Product Description 44 
Mechanism Of Action 44 
R&D Progress 44 
GS-011 – Drug Profile 46 
Product Description 46 
Mechanism Of Action 46 
R&D Progress 46 
IXC-201 – Drug Profile 47 
Product Description 47 
Mechanism Of Action 47 
R&D Progress 47 
IXC-203 – Drug Profile 48 
Product Description 48 
Mechanism Of Action 48 
R&D Progress 48 
KH-176 – Drug Profile 49 
Product Description 49 
Mechanism Of Action 49 
R&D Progress 49 
SPK-LHON – Drug Profile 51 
Product Description 51 
Mechanism Of Action 51 
R&D Progress 51 
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) – Dormant Projects 52 
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) – Product Development Milestones 53 
Featured News & Press Releases 53 
Sep 08, 2016: GenSight Biologics Receives Approval to Include Teenage Patients in RESCUE and REVERSE Phase III Trials with GS010 in Leber’s Hereditary Optic Neuropathy 53 
Jun 08, 2016: GenSight Biologics Announces Additional Promising Results of Its Phase I/II Study with GS010 for the Treatment of Leber’s Hereditary Optic Neuropathy (LHON) 54 
Jun 01, 2016: Stealth BioTherapeutics Initiates Phase 2 Study of Elamipretide in Leber’s Hereditary Optic Neuropathy 55 
Feb 29, 2016: GenSight Biologics Enrolls First Patient in Pivotal Phase III Program of GS010 in Leber’s Hereditary Optic Neuropathy 55 
Sep 10, 2015: GenSight Biologics Receives IND Acceptance from FDA to Enter Phase III with GS010 57 
Dec 15, 2014: New CMO joins Khondrion 57 
Appendix 59 
Methodology 59 
Coverage 59 
Secondary Research 59 
Primary Research 59 
Expert Panel Validation 59 
Contact Us 59 
Disclaimer 6

List of Tables 
Number of Products under Development for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy), H2 2016 8 
Number of Products under Development for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) – Comparative Analysis, H2 2016 9 
Number of Products under Development by Companies, H2 2016 10 
Number of Products under Investigation by Universities/Institutes, H2 2016 11 
Comparative Analysis by Late Stage Development, H2 2016 12 
Comparative Analysis by Clinical Stage Development, H2 2016 13 
Comparative Analysis by Early Stage Development, H2 2016 14 
Comparative Analysis by Unknown Stage Development, H2 2016 15 
Products under Development by Companies, H2 2016 16 
Products under Investigation by Universities/Institutes, H2 2016 17 
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) – Pipeline by Alkeus Pharmaceuticals, Inc., H2 2016 18 
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) – Pipeline by Biovista Inc., H2 2016 19 
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) – Pipeline by GenSight Biologics S.A., H2 2016 20 
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) – Pipeline by Ixchel Pharma, LLC, H2 2016 21
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) – Pipeline by Khondrion BV, H2 2016 22 
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) – Pipeline by Spark Therapeutics, Inc., H2 2016 23 
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) – Pipeline by Stealth BioTherapeutics Inc., H2 2016 24 
Assessment by Monotherapy Products, H2 2016 25 
Number of Products by Stage and Target, H2 2016 27 
Number of Products by Stage and Mechanism of Action, H2 2016 29 
Number of Products by Stage and Route of Administration, H2 2016 31 
Number of Products by Stage and Molecule Type, H2 2016 33 
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) – Dormant Projects, H2 2016 52

Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=693291

 

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)           

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.